KRAS and colorectal carcinoma: Through this approach, five CRC intrinsic subtypes (CRIS) were identified: (i) CRIS-A: mucinous, glycolytic, enriched for MSI or KRAS mutations; (ii) CRIS-B: transforming growth factor β (TGF-β) pathway activity, epithelial-mesenchymal transition (EMT), poor prognosis; (iii) CRIS-C: elevated EGFR signaling, sensitivity to EGFR inhibitors; (iv) CRIS-D: WNT activation, IGF2 gene overexpression and amplification; and (v) CRIS-E: Paneth cell-like phenotype, TP53 mutations.